Aurinia Pharmaceuticals
AUPH
183 hedge funds and large institutions have $429M invested in Aurinia Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 52 increasing their positions, 47 reducing their positions, and 16 closing their positions.
88% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 16
34% more capital invested
Capital invested by funds: $320M → $429M (+$109M)
11% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 47
7% more funds holding
Funds holding: 171 → 183 (+12)
1.77% more ownership
Funds ownership: 39.18% → 40.95% (+1.8%)
58% less call options, than puts
Call options by funds: $13.4M | Put options by funds: $31.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$27.6M |
| 2 |
SG Americas Securities
New York
|
+$3.32M |
| 3 |
Morgan Stanley
New York
|
+$2.99M |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$2.82M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$18.2M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
-$5.69M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$2.79M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.42M |
| 5 |
6CM
683 Capital Management
New York
|
-$2.28M |
AUPH Hedge Fund Activity: Q3 2024 in Review
183 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q3 2024, worth a combined $429M — up 34% from $320M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new AUPH positions and 16 closed out — a net gain of 14 holders — while 52 added to existing stakes and 47 trimmed.
The largest buyer was Tang Capital Management, adding an estimated $27.6M. The largest seller was Armistice Capital, cutting an estimated $18.2M.
- 183 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q3 2024, up from 171 in Q2 2024.
- Funds reported $429M of Aurinia Pharmaceuticals stock for Q3 2024, up 34% quarter-over-quarter.
- 30 funds opened new Aurinia Pharmaceuticals positions in Q3 2024 and 16 closed out, a net change of +14 holders.
- The largest Aurinia Pharmaceuticals buyer in Q3 2024 was Tang Capital Management, an estimated $27.6M added.
- The largest Aurinia Pharmaceuticals seller in Q3 2024 was Armistice Capital, an estimated $18.2M sold.
Based on aggregated 13F filings for Q3 2024.